Volume 18, Number 1—January 2012
Dispatch
Emergence of Blastoschizomyces capitatus Yeast Infections, Central Europe
Tanja Birrenbach
, Sonja Bertschy, Franziska Aebersold, Nicolas J. Mueller, Yvonne Achermann, Konrad Muehlethaler, and Stefan Zimmerli
, Sonja Bertschy, Franziska Aebersold, Nicolas J. Mueller, Yvonne Achermann, Konrad Muehlethaler, and Stefan ZimmerliTable 2
In vitro antifungal susceptibility profile according to microtiter broth dilution for patients with Blastoschizomyces capitatus yeast infections, Switzerland, June 2009–June 2010*
| Patient no. | MIC, μg/mL |
||||||
|---|---|---|---|---|---|---|---|
| AMB | 5-FC | FLC | ITC | VRC | POS | CAS | |
| 1 | 0.5 | 0.03 | 2 | 0.06 | 0.016 | 0.25 | 4 |
| 2 | 0.5 | 0.03 | 8 | 0.12 | 0.06 | 0.25 | 4 |
| 3 | 0.5 (3)† | 0.06 | 4 | 0.06 | 0.06 | 0.25 | 8 |
| 4 | 0.5 | 16 | 1 | 0.032 | 0.032 | 0.064 | 4 |
| 5 | 0.5 | 0.12 | 16 | 0.25 | 0.25 | 0.5 | >16 |
*AMB, deoxycholate amphotericin B; 5-FC, 5-fluorocytosine; FLC, fluconazole; ITC, itraconazole; VRC, voriconazole; POS, posaconazole; CAS, caspofungin.
†By Etest (bioMérieux, Marcy l’Etoile, France), the isolate had an AMB MIC of 3 μg/mL.
